Ron Bihovsky, Ph.D.

rbihovsky@keysynthesis.com

804 Primrose Lane Wynnewood, PA 19096 Phone (610) 357-3281

Organic Chemistry and Medicinal Chemistry Expert with Laboratory. Specialist in pharmaceutical patent cases requiring laboratory investigation. Testifying experience. Extensive drug discovery and lead optimization accomplishments in the pharmaceutical industry. Discovered novel, potent heterocyclic and peptide mimetic enzyme inhibitors and receptor antagonists. Good working knowledge of biochemistry and pharmacology. Good communication and interpersonal skills. Strong patent and publication record.

Expertise includes:

- Medicinal Chemistry
- Organic Synthesis
- Drug Design
- Lead Optimization

- Structure-Activity Relationships
- Molecular Modeling
- Intellectual Property
- Hatch-Waxman Patent Litigation

EXPERT WITNESS EXPERIENCE:

2001-Present KEY SYNTHESIS LLC, Wynnewood, PA. President and Founder.

- Organic chemistry and medicinal chemistry expert witness or fact witness in 20 Hatch-Waxman
 pharmaceutical patent litigation cases. Have been deposed and testified in three high-profile cases
 with favorable outcomes. Consult for intellectual property firms and perform experiments to establish
 the validity of patent claims. Perform custom organic synthesis. Specialize in pharmaceutical patent
 cases requiring laboratory investigation. Patent and literature searching capability. Wrote the genus
 and examples for my 15 granted US patents, and worked closely with patent attorneys and patent
 agents to construct the claims.
- Treasurer (2007-2008) and Chairman (2009-2012) of Chemical Consultants Network, a topical group of the American Chemical Society.

RESEARCH EXPERIENCE AND ACCOMPLISHMENTS:

2001-Present KEY SYNTHESIS LLC, Wynnewood, PA. President and Founder. Custom Organic Synthesis, Medicinal Chemistry, Expert Witness, Consultant.

Founded Key Synthesis LLC. Responsible for all aspects of the company: Located and equipped the
laboratory, developed business strategy, attracted customers. Key Synthesis prepares compounds
including enzyme inhibitors, receptor antagonists, enzyme substrates, and synthetic intermediates for
the pharmaceutical and biotechnology industries. Pharmaceutical chemistry, biotechnology, and
intellectual property consultant.

1992-2001 CEPHALON, INC., West Chester, PA. Principal Project Chemist and Senior Scientist, Medicinal Chemistry. Treatment of Cerebral Ischemia, Cancer.

 PARP Inhibitors - Principal Project Chemist: Designed novel, potent, selective heterocyclic inhibitors of poly(ADP-ribose) polymerase. Optimized potency and properties of screening hit to provide lead molecule. Lead compounds crossed blood-brain barrier, and reduced infarct volume in cerebral ischemia.



Calpain Inhibitors - Team Leader and Principal Project Chemist: Designed and synthesized novel
peptide-mimetic and non-peptide cell-permeable calpain inhibitors with new enzyme-reactive groups for
neurodegenerative therapy. Coordinated multidisciplinary team of 20 biochemists, pharmacologists, cell
biologists and medicinal chemists. Supervised team of 7-10 medicinal chemists in calpain inhibitor
program. Collaborated with directors of chemistry, biochemistry and pharmacology to evaluate
hypotheses and plan new directions. Recruited the chemistry staff. Designed the laboratories.

1987-1992 BERLEX LABORATORIES, Cedar Knolls, NJ. Scientist, Medicinal Chemistry. Cardiovascular Research.

- Project Leader Directed group of medicinal chemists in synthesis of enzyme inhibitors and peptide mimetics. Represented medicinal chemistry on core team of biochemists and pharmacologists.
- Designed and synthesized highly potent endothelin converting enzyme inhibitors.
- Investigated mechanism of epoxysuccinate class of cysteine protease inhibitors.
- Identified novel peptide-mimetic construct which was incorporated into angiotensin II.
- Performed molecular modeling on peptides, peptide mimetics, and enzyme inhibitors.

STATE UNIVERSITY OF NEW YORK, Stony Brook, NY. Assistant Professor of Chemistry. Synthetic Organic and Bio-organic Chemistry.

- Synthesized biologically significant natural products: biotin, oudenone, civet acid, C-glycoside antibiotics, lignans, tetrahydroisoquinolines.
- Generation and utilization of α-halo ethers and oxonium ions in synthesis.
- Regioselectivity of Pictet-Spengler reaction.
- Determined structures of crown gall tumor metabolites.
- Wrote computer software programs for literature reference retrieval and elemental analysis.
- Supervised research of 2 Postdoctoral Fellows, 9 Graduate Students, and 20 Undergraduates.
- Taught Graduate Synthetic Organic Chemistry and Undergraduate Organic Chemistry courses.

1978-1980 UNIVERSITY OF WISCONSIN, Madison, WI. NIH Postdoctoral Fellow. Organic Synthesis and Structure Elucidation.

- Synthesized natural products; introduced chirality via microbial transformation. Isolated and elucidated structures of compounds with smooth muscle-contracting activity (Leukotriene and G-acid) from animal tissue; determined mechanism of action.
- Performed smooth-muscle contractility assays.

1972-1978 UNIVERSITY OF CALIFORNIA, Berkeley, CA. Graduate student, Organic Chemistry. Organic Synthesis and Structure Elucidation.

- Synthesized anatoxin-a via intramolecular cyclization of iminium ion.
- Isolated and determined structure of saxitoxin, potent marine neurotoxin.
- Developed sensitive oxidative fluorescence assay for saxitoxin.
- Cultured microscopic marine algae, isolated toxins, performed bioassay, and determined structures.

Additional Academic Experience:

2001-2003 Villanova University, Villanova, PA. Adjunct Professor of Chemistry.

• Created and taught graduate Medicinal Chemistry course.

Education: Ph.D. 1977, Organic Chemistry, University of California, Berkeley (Advisor: H. Rapoport)

B.S. 1970, Chemistry, Magna cum laude, Honors in Chemistry,

State University of New York, Stony Brook

Languages: Reading and Speaking – German

Scientific Reading - French, Italian, Spanish

Computer Windows, UNIX, Fortran, Basic, ISIS Base, Beilstein, CAS-Scifinder,

Experience: Excel, Word, Powerpoint, Netscape, Internet Explorer, etc.



Publications: (Note: Ron Bihovsky previously published under the name H. Bates)

- 1. M. Tao,* C. H. Park, R. Bihovsky, G. J. Wells, J. Husten, M. A. Ator, R. L. Hudkins, "Synthesis and Structure-Activity Relationships of Novel Poly(ADP-ribose) Polymerase-1 Inhibitors." *Bioorg. Med. Chem. Lett.* 16, 938-942 (2006).
- 2. G. W. Wells,* R. Bihovsky, R. L. Hudkins, M. A. Ator, and J. Husten, "Synthesis and Structure-Activity Relationships of Novel Pyrrolocarbazole Lactam Analogs as Potent and Cell-Permeable Inhibitors of Poly(ADP-ribose)polymerase-1 (PARP-1)." *Bioorg. Med. Chem. Lett.* 16, 1151-1155 (2006).
- 3. R. Bihovsky, M. Tao, J. P. Mallamo, and G. Wells,* "1,2-Benzothiazine 1,1-Dioxide α-Ketoamide Analogues as Potent Calpain I Inhibitors." *Bioorg. Med. Chem. Lett.* 14, 1035-1038 (2004).
- 4. S. J. Miknyoczki, S. Jones-Bolin, S. Pritchard, K. Hunter, H. Zhao, W. Wan, M. Ator, R. Bihovsky, R. Hudkins, S. Chatterjee, A. Klein-Szanto, C. Dionne, and B. Ruggeri, "Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor." *Mol. Cancer Ther.* 2, 371-382 (2003).
- 5. G. J. Wells, M. Tao, K. A. Josef, and R. Bihovsky,* "1,2-Benzothiazine 1,1-dioxide P₂ P₃ Peptide Mimetic Aldehyde Calpain I Inhibitors." *J. Med. Chem. 44*, 3488-3503 (2001).
- 6. K. A. Josef,* F. W. Kauer, and R. Bihovsky, "Potent α-Ketohydroxamate Inhibitors of Recombinant Human Calpain I." *Bioorg. Med. Chem. Lett. 11*, 2615-2617 (2001).
- 7. S. Chatterjee,* D. Dunn, M. Tao, G. Wells, Z.-Q. Gu, R. Bihovsky, M. A. Ator, R. Siman, and J. P. Mallamo, "P₂-Achiral, P'-Extended α-Ketoamide Inhibitors of Calpain." *Bioorg. Med. Chem. Lett.* 9, 2371-2374 (1999).
- 8. G. J. Wells* and R. Bihovsky, "Calpain Inhibitors as Potential Treatment for Stroke and Other Neurodegenerative Diseases. Recent Trends and Developments." *Expert Opin. Ther. Patents 8,* 1707-1727 (1998).
- 9. M. Tao,* R. Bihovsky, G. J. Wells, and J. P. Mallamo, "Novel Peptidyl Phosphorous Derivatives as Inhibitors of Human Calpain I." *J. Med. Chem. 41*, 3912-3916 (1998).
- 10. S. Chatterjee,* Z.-Q. Gu, D. Dunn, M. Tao, K. Josef, R. Tripathy, R. Bihovsky, S. E. Senadhi, T. M. O'Kane, B. A. McKenna, S. Mallya, M. A. Ator, D. Bozyczko-Coyne, R. Siman, and J. P. Mallamo, "D-Amino Acid Containing High Affinity Inhibitors of Recombinant Human Calpain I." *J. Med. Chem.* 41, 2663-2666 (1998).
- 11. S. Chatterjee,* M. A. Ator, D. Bozyczko-Coyne, K. Josef, G. Wells, R. Tripathy, M. Iqbal, R. Bihovsky, S. Mallya, S. E. Senadhi, T. M. O'Kane, B. A. McKenna, R. Siman, and J. P. Mallamo, "Synthesis and Biological Activity of a Series of Potent Fluoromethyl Ketone Inhibitors of Recombinant Human Calpain I." *J. Med. Chem. 40*, 3820-3828 (1997).
- 12. R. Bihovsky* and M. A. Ator, "Calpains: Their Role in Pathology, and New Therapeutic Opportunities." Investigational Drugs Weekly Highlights, 22-25, May, 1997.
- 13. M. Iqbal, P. Messina, B. Freed, M. Das, S. Chatterjee, R. Tripathy, M. Tao, K. A. Josef, B. Dembofsky, D. Dunn, E. Griffith, R. Siman, S. E. Senadhi, W. Biazzo, D. Bozyczko-Coyne, S. L. Meyer, M. A. Ator, and R. Bihovsky*, "Subsite Requirements for Peptide Aldehyde Inhibitors of human Calpain I." *Bioorg. Med. Chem. Lett.*, 7, 539-544 (1997).
- 14. M. Tao*, R. Bihovsky, and J. C. Kauer "Inhibition of Calpain by Peptidyl Heterocycles." *Bioorg. Med. Chem. Lett.*, *6*, 3009-3012 (1996).



- 15. R. Bihovsky*, and I. Pendrak, "Synthesis of Cystamidin A (Pyrrole-3-propanamide), a Reported Calpain Inhibitor." *Bioorg. Med. Chem. Lett.*, *6*, 1541-1542 (1996).
- S. Chatterjee*, K. Josef, G. Wells, M. Iqbal, R. Bihovsky, J. P. Mallamo, M. Ator, D. Bozyczko-Coyne, S. Mallya, S. Senadhi, and R. Siman "Potent Fluoromethyl Ketone Inhibitors of Recombinant Human Calpain I." *Bioorg. Med. Chem. Lett.*, 6, 1237-1240 (1996).
- 17. S. L. Meyer*, D. Bozyczko-Coyne, S. K. Mallya, C. M. Spais, R. Bihovsky, J. K. Kawooya, D. M. Lang, R. W. Scott, and R. Siman "Biologically Active Monomeric and Heterodimeric Recombinant Human Calpain I Produced Using the Baculovirus Expression System". *Biochem. J.* 314, 511-519 (1996).
- 18. R. Bihovsky*, B. Levinson, R. Loewi, P. W. Erhardt, and M. Polokoff, "Hydroxamic Acids as Potent inhibitors of Endothelin Converting Enzyme," *J. Med. Chem.* 38, 2119-2129 (1995).
- 19. R. Bihovsky*, J. C. Powers, C.-M. Kam, R. Walton, and R. Loewi, "Further Evidence for the Importance of Free Carboxylate in Epoxysuccinate Inhibitors of Thiol Proteases," *J. Enzyme Inhib.* 7, 15-25 (1993).
- 20. R. Bihovsky*, "Reactions of α , β -Epoxy Carbonyl Compounds with Methanethiolate: Regioselectivity and Rate," *J. Org. Chem.*, *57*, 1029-1031 (1992).
- 21. R. Bihovsky*, "Applications of Cyclic α-Haloethers and Unsaturated Oxonium Ions to Natural Product Synthesis: Carbon-Carbon Bond Formation," *Trends in Organic Chemistry*, *3*, 1-6 (1992).
- 22. R. Mohan*, Y. L. Chou, R. Bihovsky, W. C. Lumma, Jr. P. Erhardt, and K. Shaw, "Synthesis and Biological Activity of Angiotensin II Analogs Containing a Val-His Replacement, ValΨ[CH(CONH₂)NH]His," *J. Med. Chem.*, 34, 2402-2410, (1991).
- 23. S. Rosenblum and R. Bihovsky*, "Synthesis of the Papulacandin *C*-Arylglucosylspiroketal Nucleus," *J. Amer. Chem. Soc., 112,* 2746-2748 (1990).
- R. Bihovsky* and V. Bodepudi, "Synthesis of (+)-Biotin: Efficient Resolution of Key Intermediates," Tetrahedron, 46, 7667-7676, (1990).
- 25. R. Bihovsky*, M. U. Kumar, S. Ding, and A. Goyal, "Oxonium Ions in Organic Synthesis: Condensation of 2,3-Dihydrofuran and 3,4-Dihydro-2*H*-pyran with 1,3-Dicarbonyl Compounds," *J. Org. Chem., 54*, 4291-4293 (1989).
- 26. R. Bihovsky*, C. Selick, and I. Giusti, "Synthesis of *C*-Glucosides by Reactions of Glucosyl Halides with Oranocuprates," *J. Org. Chem.*, *53*, 4026-4031 (1988).
- 27. H. Bates*, K. Bagheri, and P. Vertino, "Effect of pH on the Regioselectivity of Pictet-Spengler Reactions of 3-Hydroxyphenethylamines with Formaldehyde and Acetaldehyde," *J. Org. Chem. 51*, 3061-3063 (1986).
- 28. H. Bates*, J. Farina, and M. Tong, "An Approach to Pseudomonic Acids from Acetylenic Precursors: Synthesis of 2-(Hydroxymethyl)-3-butyn-1-ol," *J. Org. Chem., 51*, 2637-2641 (1986).
- 29. H. Bates* and S. Rosenblum, "Nucleophilic Displacements on an α-Chlorothioether by Organocuprates: A Novel Synthesis of Desoxybiotin," *J. Org. Chem., 51,* 3447-3451 (1986).
- 30. H. Bates, "Structure of Crown Gall Tumor Metabolites: Chemical Mediators of Parasitism," *Anal. New York Acad. Sci.*, *471*, 289-290 (1986).



- H. Bates*, N. Condulis, and N. Stein, "Reduction of Cyclic Ureas with Lithium Aluminum Hydride," J. Org. Chem., 51, 2228-2229 (1986).
- 32. H. Bates*, J. Magrath, and A. Kaushal, "A Direct Method for Assignment of Absolute Configurations in Crown Gall Metabolites: The Structure of Nopaline," *J. Nat. Prod., 48,* 598-601 (1985).
- 33. H. Bates* and J. Farina, "Oxonium Ion Electrophiles: Synthesis of the Hypotensive Oudenone," *J. Org. Chem.*, *50*, 3843-3845 (1985).
- 34. H. Bates* and S. Rosenblum, "300 MHz ¹H NMR Spectra and Conformations of Biotin and Related Hexahydrothienoimidazolone Derivatives," *Tetrahedron Lett., 41,* 2331-2336 (1985).
- 35. H. Bates*, L. Smilowitz, and S. Rosenblum, "A Practical Stereospecific Synthesis of the Biotin Precursor (3aα,6aα)-1,3-Dibenzylhexahydro-1*H*-thieno[3,4-d]imidazol-2(3*H*)-one 1,1-Dioxide," *J. Chem. Soc., Chem. Commun.*, 353-354 (1985).
- 36. H. Bates* and C. Selick, "Convenient Preparation of 2,3,4,6-Tetra-*O*-Methyl-α-D-Glucopyranosyl Bromide," *J. Carbohydr. Chem.*, *4*, 273-275 (1985).
- 37. H. Bates*, L. Smilowitz, and J. Lin, "Preparation of (3aα,6aα)-1,3-Dibenzylhexahydro-1*H*-thieno[3,4-d]imidazol-2(3*H*)-one: A Key Biotin Intermediate," *J. Org. Chem.*, *50*, 899-901 (1985).
- 38. H. Bates* and J. Garelick, "Synthesis of Tetrahydro-4,6,7-Isoquinolinetriols and Tetrahydro-4,7,8-isoquinolinetriols," *J. Org. Chem., 49,* 4552-4557 (1984).
- 39. H. Bates*, A. Kaushal, P. Deng, and D. Sciaky, "Structure and Synthesis of Histopine, a Histidine Derivative Produced by Crown Gall Tumors," *Biochemistry*, 23, 3287-3290 (1984).
- 40. H. Bates* and P. Deng, "Synthesis of the Civet Constituent *cis*-(6-Methyltetrahydropyran-2-yl)acetic Acid," *J. Org. Chem., 48*, 4479-4481 (1983).
- 41. H. Bates, "Characterization of Tetrahydroisoquinolines Produced by Pictet-Spengler Reactions of Norepinephrine with Formaldehyde and Acetaldehyde," *J. Org. Chem., 48,* 1932-1934 (1983).
- 42. H. Bates, "Decarbonylation of Tetrahydrofuran-2-carboxylic Acids and Tetrahydropyran-2-carboxylic Acids in Concentrated Sulfuric Acid: Formation of Oxonium Ions," *J. Am. Chem. Soc., 104,* 2490-2493 (1982).
- 43. H. Bates*, "Pictet-Spengler Reactions of Epinephrine with Formaldehyde," *J. Org. Chem., 46*, 4931-4935 (1981).
- 44. H. Bates and C. Sih*, "Arachidonic Acid is Responsible for the Smooth Muscle-Contracting Activity of G-Acid," *Proc. Nat. Acad. Sci., 76,* 2712-2714 (1979).
- 45. H. Bates and H. Rapoport*, "Synthesis of Anatoxin a via Intramolecular Cyclization of Iminium Salts," *J. Am. Chem. Soc.*, *101*, 1259-1265 (1979).
- 46. H. Bates, R. Kostriken, and H. Rapoport*, "The Occurrence of Saxitoxin and Other Toxins in Various Dinoflagellates," *Toxicon*, *16*, 595-601 (1978).
- 47. H. Bates, R. Kostriken, and H. Rapoport*, "A Chemical Assay for Saxitoxin: Improvements and Modifications," *J. Agr. Food Chem., 26,* 252-254 (1978).
- 48. J. Bordner, W. Thiessen, H. Bates, and H. Rapoport*, "The Structure of a Crystalline Derivative of Saxitoxin." *J. Am. Chem. Soc.*, *97*, 6008-6012 (1975).



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

